Developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases


Allena Pharmaceuticals, Inc. is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases. Allena is currently conducting two Phase 2 clinical trials of its lead product candidate, ALLN-177, in patients with hyperoxaluria. The company’s technological approach enables the design and development of oral protein therapies that remain in the gastrointestinal (GI) tract, where the protein exerts its therapeutic effect by degrading metabolites, without being absorbed into the bloodstream.


Year Invested: 2011
Location: Newton, Mass.
Visit: www.allenapharma.com

Recent News

January 5, 2017
Allena Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference

October 4, 2016
Allena Pharmaceuticals and Health Advances Present Analysis of Recurrent Kidney Stone Disease at the Academy of Managed Care Pharmacy Nexus Conference

September 7, 2016
Allena Pharmaceuticals Strengthens Leadership Team, Names Edward Wholihan As Chief Financial Officer And Robert Alexander, Phd, To Board Of Directors

Read More News

Associated Team Members

Robert Tepper, M.D.
Partner